News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Advanced Catheter Therapies Receives Second Patent on OPC


9/14/2012 9:12:13 AM

CHATTANOOGA, TN--(Marketwire - September 14, 2012) -

Advanced Catheter Therapies, Inc. (ACT) (www.acatheter.com), today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8262611 for its catheter technology.

The patent, entitled "Occlusion Perfusion Catheter," was issued on September 11, 2012 and is closely related to the U.S. Patent No. 8088103 issued to ACT in early 2012 for its catheter technology. The company now has two U.S. patents with a total of 31 claims, one pending U.S. method patent and five pending international patents.

The Occlusion Perfusion Catheter™ (OPC) is a multi-lumen balloon catheter designed to temporarily occlude a specific region from blood flow to allow the local delivery of therapeutic agents to the peripheral and eventually the coronary vasculature. The OPC has the ability to create a localized treatment chamber for the delivery of various types of therapeutic agents, including pharmaceuticals, live cells and biologics, to treat a variety of disease states and place the agent circumferentially into the vasculature of the treatment chamber.

The OPC is unique in its ability to measure pressure applied inside the treatment chamber and its inflow and outflow ports for chamber evacuation, filling and flushing. The OPC affords clinicians substantial procedural control as well as the ability to select the treatment agent and volume along with preventing systemic release of the treatment agent.

ACT recently announced that it has contracted with Hatch Medical, L.L.C. (www.hatchmedical.com) to assist with licensing or forming a strategic partnership for the OPC, the company's lead vascular catheter product. Also in the company's development pipeline are devices to improve endovascular debulking procedures (the clearing of blocked blood vessels).

"We are very pleased to further strengthen our intellectual property platform with this patent," said Paul J. Fitzpatrick, CEO of ACT. "We continue to move the OPC closer to commercialization while exploring new tools to help support physicians in their work."

About ACT
Advanced Catheter Therapies, an early stage research and development medical device company, has a portfolio of innovative catheter technologies targeting vascular disease including thrombosis, inflammation, occlusions and restenosis. www.acatheter.com


Media inquiries:
Lynn Hood
Email Contact
678-427-5040

ACT contact:
Paul Fitzpatrick
Email Contact
770-321-8439

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES